CORT INVESTIGATION REMINDER: Corcept Therapeutics Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

NodeGuardian · 2026-02-20T20:01:24+00:00

Kaplan Fox & Kilsheimer LLP is probing Corcept Therapeutics, Inc. for securities law violations after significant stock declines due to FDA feedback on relacorilant's effectiveness and prior warnings about its clinical program.

NodeGuardian

2026-02-20 20:01:24

Abstract generation in progress

Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Corcept Therapeutics, Inc. (NASDAQ: CORT) following two significant stock drops. The first occurred after the FDA issued a Complete Response Letter for relacorilant, citing insufficient evidence of effectiveness, causing a 50% stock decline. A subsequent correction to the CRL revealed the FDA had previously warned Corcept about the inadequacy of its clinical program, leading to another 12% drop.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.